PROLOR Biotech to Present at Oppenheimer 22nd Annual Healthcare Conference

NES-ZIONA, Israel, Dec. 7, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011 at 1:35 PM EST. The conference is being held December 13-14, 2011 at the Waldorf Astoria Hotel in New York City.

A live webcast of the company’s presentation will be available at the Investors section of PROLOR’s website at www.prolor-biotech.com/?CategoryID=215, or at http://www.veracast.com/webcasts/opco/healthcare2011/94214603.cfm. An archived version of the webcast will be available for 90 days beginning about three hours after the live presentation.

For more information about the Oppenheimer 22nd Annual Healthcare Conference, visit http://www.opco.com/Conferences/healthcare11/index.html.

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins. PROLOR is currently developing a long-acting version of human growth hormone, which has successfully completed a Phase II clinical trial. It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, as well as agents for atherosclerosis and rheumatoid arthritis, which are all in preclinical development. For more information, visit www.prolor-biotech.com.

SOURCE PROLOR Biotech, Inc.